Curiteva, a medical technology company, successfully treated more than 5,000 stages with the Inspire Cervical implant, just two years after its first surgical operation in April 2023. This milestone shows the continued introduction of the new 3D -printed trabecular PEEK implant.
“I have seen remarkable radiological evidence with the Inspire platform, including visible bone growth in the graft window and through the implant within only 3 to 6 months. This offers clinicians an incomparable ability to reliably assess healing and progress,” said Chambliss Harrod, MD of the spine center of Louisiana.
“With this implant, I often only need a little or no tension and have a lot more confidence in the merger rates and the satisfaction of the patients during the multi -stage ACDF procedure as well as the satisfaction of the patients,” said John Johnson, MD of Sportsmedic Surgery and Spine Center in Alabama.
“After 30 years with allotranslantat, I have finally found a practical replacement for bones. These Curiteva implants can not only revolutionize the spine supply, but also a wide range of other applications in which bones could have been used beforehand. This technology has set a new standard in patient care through the innovative design and the extraordinary biomechanical and potential biological properties.
Developed with the proprietary and internally developed FFF -3D printers from Curiteva. Impire implants have a completely connected and integrated porous structure that crosses the entire implant. In combination with the Hafuse-Sub-Micron Nanotexturing, the Inspire implant promotes growing and creates a superior biological environment for bone integration.
Curiteva plans a complete commercial publication after a successful Alpha start of the Inspire Tlif Anterior and Inspire Tlif Oblique Implants during this month. In addition, the Alpha -Starts company will introduce its Alif portfolio, which includes monolithic, thoracolumbalic plates and independent implants in the course of this year.
“These successes reflect the synergy of innovative technology, the production of world class, living partnerships and clinical trust,” said Chad Falciani, founder and chairman of the Curiteva board.